Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Sold 3.8K
Sold 22.4K
Sold 5.1K
Granted 472
Sold 33
Granted 943 · Sold 318
Granted 943
Granted 472
Granted 472
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Liu JoyEVP and Chief Legal Officer · 4 transactions | +61.6% | 20.0K | — | — | 3.8K |
| Bozic CarmenEVP and CMO · 9 transactions | -59.4% | 15.3K | — | — | 22.4K |
| McKechnie DuncanEVP, Chief Commercial Officer · 2 transactions | -37.5% | 12.5K | — | — | 5.1K |
| Garber Alan MDirector · 1 transaction | +6.9% | 7.3K | 472 | — | — |
| Bunnage Mark E.EVP, Chief Scientific Officer · 1 transaction | 0% | 7.3K | — | — | 33 |
| Bhatia Sangeeta N.Director · 2 transactions | +14.5% | 4.9K | 943 | — | 318 |
| McKenzie DianaDirector · 2 transactions | +38.7% | 3.4K | 943 | — | — |
| Schneider JenniferDirector · 2 transactions | +27.5% | 2.2K | 472 | — | — |
| Thornberry NancyDirector · 2 transactions | +3.6% | 2.1K | 472 | — | — |
| Upadhyay SuketuDirector · 1 transaction | -33.8% | 1.6K | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -31.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.